-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Follicular Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Peritoneal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Peritoneal Cancer Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Epithelial Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Epithelial Ovarian CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Refractory Multiple MyelomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Follicular LymphomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Fallopian Tube CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Peritoneal CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Cutaneous T-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Cutaneous T-Cell Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Colorectal Cancer Drug Details: Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s-malate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Melanoma Drug Details: Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s-malate salt...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.